HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy; Reports Phase 2 Study Results

Hyperion Therapeutics

announced today that the results of the Phase 2 HALT-HE Study were presented at the Presidential Plenary Session I of the 63^rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) (The Liver Meeting®), in Boston, MA. Principal Investigator Don Rockey, Chief of Medicine at the Medical University of South Carolina delivered an oral presentation entitled, Randomized, controlled, double-blind study of glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy. Dr. Rockey explained, "The study results provide new insight into the importance of ammonia in the pathogenesis of hepatic encephalopathy (HE). Based on its safety profile, Hyperion's investigational drug, glycerol phenylbutyrate (GPB), or "Ravicti", shows promise as a novel therapeutic agent."